NFKB1 and fatty liver disease: In AT, the activation of p53 promotes the expression of pro-inflammatory adipokines through NF-κB signaling, leading to hepatic steatosis, IR and diabetes, while inhibition of p53 activity impairs inflammation and attenuates hepatic steatosis (185, 188).